309 related articles for article (PubMed ID: 25773260)
1. Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report.
Cendales L; Bray R; Gebel H; Brewster L; Elbein R; Farthing D; Song M; Parker D; Stillman A; Pearson T; Kirk AD
Am J Transplant; 2015 Aug; 15(8):2250-5. PubMed ID: 25773260
[TBL] [Abstract][Full Text] [Related]
2. De novo belatacept in clinical vascularized composite allotransplantation.
Cendales LC; Ruch DS; Cardones AR; Potter G; Dooley J; Dore D; Orr J; Ruskin G; Song M; Chen DF; Selim MA; Kirk AD
Am J Transplant; 2018 Jul; 18(7):1804-1809. PubMed ID: 29723921
[TBL] [Abstract][Full Text] [Related]
3. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
5. Benefits and limitations of belatacept in 4 hand-transplanted patients.
Grahammer J; Weissenbacher A; Zelger BG; Zelger B; Boesmueller C; Ninkovic M; Mühlbacher A; Peschel I; Brandacher G; Öfner D; Schneeberger S
Am J Transplant; 2017 Dec; 17(12):3228-3235. PubMed ID: 28742936
[TBL] [Abstract][Full Text] [Related]
6. Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients.
Tawhari I; Hallak P; Bin S; Yamani F; Safar-Boueri M; Irshad A; Leventhal J; Ansari MJ; Cravedi P; Gallon L
Front Immunol; 2022; 13():1096881. PubMed ID: 36601111
[TBL] [Abstract][Full Text] [Related]
7. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
[TBL] [Abstract][Full Text] [Related]
8. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients.
Mujtaba MA; Sharfuddin AA; Taber T; Chen J; Phillips CL; Goble M; Fridell JA
Am J Transplant; 2014 Nov; 14(11):2657-61. PubMed ID: 25179306
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
10. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
11. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
Gupta G; Regmi A; Kumar D; Posner S; Posner MP; Sharma A; Cotterell A; Bhati CS; Kimball P; Massey HD; King AL
Am J Transplant; 2015 Oct; 15(10):2726-31. PubMed ID: 25988397
[TBL] [Abstract][Full Text] [Related]
12. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
13. Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review.
Lombardi Y; François H
Front Med (Lausanne); 2022; 9():942665. PubMed ID: 35911396
[TBL] [Abstract][Full Text] [Related]
14. Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome.
Tatapudi VS; Lonze BE; Wu M; Montgomery RA
Case Rep Nephrol Dial; 2018; 8(1):10-19. PubMed ID: 29594146
[TBL] [Abstract][Full Text] [Related]
15. Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial.
Mannon RB; Armstrong B; Stock PG; Mehta AK; Farris AB; Watson N; Morrison Y; Sarwal M; Sigdel T; Bridges N; Robien M; Newell KA; Larsen CP
Am J Transplant; 2020 Dec; 20(12):3599-3608. PubMed ID: 32558199
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.
de Graav GN; Baan CC; Clahsen-van Groningen MC; Kraaijeveld R; Dieterich M; Verschoor W; von der Thusen JH; Roelen DL; Cadogan M; van de Wetering J; van Rosmalen J; Weimar W; Hesselink DA
Transplantation; 2017 Oct; 101(10):2571-2581. PubMed ID: 28403127
[TBL] [Abstract][Full Text] [Related]
19. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation.
Diaz-Siso JR; Fischer S; Sisk GC; Bueno E; Kueckelhaus M; Talbot S; Carty MJ; Treister NS; Marty F; Milford EL; Pomahac B; Tullius SG
Am J Transplant; 2015 May; 15(5):1421-31. PubMed ID: 25777324
[TBL] [Abstract][Full Text] [Related]
20. Costimulation Blockade in Vascularized Composite Allotransplantation.
Giannis D; Moris D; Cendales LC
Front Immunol; 2020; 11():544186. PubMed ID: 33042138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
